Happy Autumn to all! My name is Stephan Haitz, and I joined the CordenPharma team in June 2024 as Chief Commercial Officer.
The recent CPHI show, 8-10 October in Milan, Italy, allowed me to meet the most important element of every CDMO – our valued customers. At our beautiful booth the CordenPharma team held many fruitful meetings with our customers to discuss our broad capabilities across 6 technology platforms.
I enjoyed seeing our capable commercial team and technical experts in action and look forward to continuing these external and internal conversations going forward.
The CordenPharma Commercial Team gathers for CPHI Milan, 8-10 October in Italy.
Prior to the CPhI Show in Milano, it has been an exciting and educational experience to get to know our talented people – from executive leaders to sales, marketing, project management and facility teams across our global network – revealing the bright future ahead for CordenPharma. The amount of investment CordenPharma has made over the last year in technology and assets to support the growing demand to supply much-needed medication to patients is truly impressive. After visiting all our sites, I saw firsthand how these investments will enhance our service offerings and bring added value to customers.
My journey began with a visit to our CordenPharma Colorado (Boulder, US) site under our Peptide platform. As mentioned by CEO Dr. Michael Quirmbach in our last newsletter, we announced large-scale peptide manufacturing expansions both in Colorado and in Switzerland, with the construction of a new greenfield manufacturing facility. It was therefore very exciting to visit the CordenPharma Colorado facility and see firsthand not only the previous expansions now in full operation, but also the scale and vision of the new expansions planned over the next couple of years. At a visit to our Frankfurt (DE) site, we received approval for a new GMP line to manufacture early clinical-phase peptide APIs, further expanding our ability to support customers in the peptide platform.
Just in the same neighborhood at our Plankstadt (DE) site, I learned how we will soon receive approval for our new GMP Clinical Trial Development facility, designed specifically for the delivery of up to 80 kg of highly potent Oral Solid Dosage drug products under our Highly Potent & Oncology platform, helping customers get their important programs advanced through the clinical phases faster.
For our Small Molecules platform I traveled south to help inaugurate the expansion of our Chenôve (FR) site with new 6m3 reactors, agitated filter dryers and centrifuges to strengthen our drug substance API capabilities. Then, even further south, I attended the inauguration of new oral solid dosage tablet coating equipment at our Lisbon, PT site, and finally, at our Bergamo (IT) site in Italy I visited the ongoing expansion projects increasing our overall capacity with the addition of a new CDMO API manufacturing line, including additional warehousing storage on site.
Not far away at our Caponago (IT) site under our Injectables platform the new LNP (Lipid NanoParticle) GMP clinical to commercial manufacturing suite was indeed very impressive. No wonder many innovative pharma companies trust us to help develop their LNP-based therapeutics.
And finally, closer to home, I visited our Liestal (CH) site under the Lipids & Carbohydrates platform to see our latest expansion in small-scale GMP manufacturing and purification capacity, including our sustainable Supercritical Fluid Chromatography (SFC) technology for highly efficient manufacturing of effective Catalog Lipids and LNP Starter Kits for xRNA-based therapeutic development.
In those first months I discovered our organization is built on a strong foundation of expertise and innovation with passionate employees working hard every day to keep your project goals and commercial success at the forefront of every decision.
I learned that what sets CordenPharma apart – the core of CordenPharma – is our Integrated Supply model, which draws upon a global facility network and transparent project management teams for seamless integration of services across your drug lifecycle, from development to commercialization. We augment that with strong partnerships such as RNA manufacturing through our partners WACKER Biotech.
My goal over the coming months is to identify and implement ways to drive our services to maximize integrated supply synergies for your benefit, creating more efficient workstreams, information flow and, with our colleagues, work on ESG initiatives to support your supply chain sustainability.
Thank you again for being a loyal and valued customer! We look forward to meeting existing and new customers at the upcoming scheduled events throughout the year.
To conclude, feel free to reach out to your respective Account Managers to schedule a meeting or provide any feedback on how we can better serve you – with the ultimate goal of being your true end-to-end CDMO partner.
Dr. Stephan Haitz
Chief Commercial Officer
CordenPharma
Want to find out more?
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.